

REMARKS

A. The claims are not anticipated under 35 U.S.C. §102(b)

Claims 1 - 4, 6, 13 - 16, 18, 25, 26, 28, 30, 31, 33 and 35 stand rejected under 35 U.S.C. §102(b) as being anticipated by Banknieder et al., U.S. Patent 4,751,243.

The Action states that the Banknieder reference is asserted in support of this rejection because, despite the fact acknowledged in the Action that Banknieder teaches systemic administration of the aldose reductase inhibitor, tolrestat (the compound N-[[5-(trifluoromethyl)-6-methoxy-1-naphthenyl]-thioxomethyl]-N-methylglycine), the wound will be "contacted" by the compound as a result of systemic distribution of the compound. Although Applicants disagree with this interpretation, they have amended the pending claims to recite that the wound is exposed to an aldose reductase inhibitor compound by topical application of the compound to the wound. Applicants respectfully contend that this amendment fully addresses the bases for the rejection under 35 U.S.C. §102(b), and respectfully ask the Examiner to withdraw the rejection.

B. The claims are not obvious under 35 U.S.C. §103(a)

Claims 1-4, 6-7, 13-16, 18-19, 25-26, 28-31, 33-34 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Banknieder et al.

Applicants respectfully contend that the deficiencies of the Banknieder reference set forth above apply with equal force to the rejection based on obviousness. The amendments Applicants submit herewith to the claims sufficiently distinguish the instantly claimed invention from the teachings of the Banknieder reference, and thus respectfully ask the Examiner to withdraw this ground or rejection.


CONCLUSIONS

It is believed that all requirements of patentability are fully met, and allowance of the claims is respectfully requested.

If the Examiner believes it to be helpful, the Examiner is invited to contact the undersigned attorney by telephone at (312) 913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By:



Kevin E. Noonan, Ph.D.
Registration No. 35,303

Date: September 28, 2004